Biomednewsbreaks - Calidi Biotherapeutics Inc. (NYSE American: CLDI) Announces Public Offering Of Common Stock And Warrants

(MENAFN- Investor Brand Network) Calidi Biotherapeutics (NYSE American: CLDI) , a clinical-stage biotechnology company focused on advanced immunotherapies, announced plans to offer shares of its common stock and/or pre-funded warrants in a public offering. Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent. The offering's size and terms depend on market conditions and are yet to be finalized. Proceeds will support working capital and general corporate purposes. The securities will be offered under an effective shelf registration statement filed with the SEC, and interested parties can access the preliminary prospectus and accompanying documents via the SEC website or through Ladenburg Thalmann's Prospectus Department.

To view the full press release, visit:

About Calidi Biotherapeutics

Calidi Biotherapeutics specializes in proprietary technology that empowers the immune system to combat cancer. The company's novel stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi's clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi's preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California.

For more information, please visit

NOTE TO INVESTORS:
The latest news and updates relating to CLDI are available in the company's newsroom at

About BioMedWire

BioMedWire
(“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the
Dynamic Brand Portfolio
@
IBN
that delivers :
(1) access to a vast network of wire solutions via
InvestorWire
to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ;
(2) article and
editorial syndication to 5,000+ outlets ;
(3) enhanced
press release enhancement
to ensure maximum impact ;
(4)
social media distribution
via IBN to millions of social media followers ;
and (5) a full array of tailored
corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire,“Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:
/Disclaimer

BioMedWire
Austin, Texas

512.354.7000 Office
[email protected]

BioMedWire is powered by
IBN

MENAFN10012025000224011066ID1109077459